Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 21 (9), 48

Cardiovascular Safety of Urate Lowering Therapies

Affiliations
Review

Cardiovascular Safety of Urate Lowering Therapies

Eun Ha Kang et al. Curr Rheumatol Rep.

Abstract

Purpose of review: The effect of urate lowering treatment (ULT) on cardiovascular (CV) risk and mortality in gout has been a topic of interest. This review discusses the CV effect of ULT and comparative CV safety among ULT agents.

Recent findings: The mechanism linking gout with CV risk is not fully understood but seems multifactorial involving hyperuricemia, xanthine oxidase (XO), oxidative stress, and chronic inflammation. Conflicting data exist regarding CV benefits of ULT in adults with and without hyperuricemia. Although meta-analyses on randomized controlled trials (RCTs) suggest CV benefits with allopurinol, few high-quality RCTs have examined the CV effect of ULT among patients with hyperuricemia or gout. The recent CARES trial adds new information on comparative CV safety between two XO inhibitors (XOIs), febuxostat and allopurinol, in patients with gout. It remains unclear whether ULT reduces CV risk in patients with gout or hyperuricemia. Comparative CV safety studies of XOIs suggest that additional mechanisms beyond urate-lowering effect or XO inhibition are likely involved in CV risk modification in patients with gout. Ongoing RCTs of ULT may be able to further determine the effect of ULT on CV risk.

Keywords: Allopurinol; Cardiovascular; Febuxostat; Gout, hyperuricemia; Urate lowering treatment.

Similar articles

See all similar articles

References

    1. Am J Physiol Renal Physiol. 2002 Jun;282(6):F991-7 - PubMed
    1. Circulation. 2002 Jun 4;105(22):2619-24 - PubMed
    1. Circulation. 2002 Jul 9;106(2):221-6 - PubMed
    1. Circulation. 2002 Dec 10;106(24):3073-8 - PubMed
    1. Arthritis Rheum. 2002 Dec 15;47(6):610-3 - PubMed

LinkOut - more resources

Feedback